Best Researcher Award
David Suran — Maribor University Medical Centre
David Suran is a Slovenian clinician-scientist associated with Maribor University Medical Centre whose academic contributions focus on cardiovascular pharmacology, myocardial infarction research, renal complications in cardiovascular disease, and clinical cardiology. His published works demonstrate interdisciplinary engagement in cardiology, nephrology, internal medicine, and evidence-based cardiovascular outcomes research. Through extensive clinical investigations and collaborative medical publications, Suran has contributed to the understanding of myocardial infarction management, acute kidney injury, atrial fibrillation, cardiovascular risk assessment, and translational clinical medicine.[1]
Abstract
This academic article presents a structured overview of the research profile and scholarly contributions of David Suran in the fields of cardiovascular medicine and cardiovascular pharmacology. The article summarizes publication trends, citation indicators, collaborative clinical investigations, and thematic areas of research related to myocardial infarction, atrial fibrillation, acute kidney injury, cardiovascular outcomes, and evidence-based medicine. It further evaluates the suitability of the researcher for recognition under the Best Researcher Award category associated with the International Top Pharmaceutical Awards. The analysis reflects the researcher’s sustained participation in peer-reviewed scientific communication and clinically oriented medical investigations.[2]
Keywords
Cardiovascular Pharmacology, Myocardial Infarction, Acute Kidney Injury, Clinical Cardiology, Cardiovascular Outcomes, Internal Medicine, Atrial Fibrillation, Evidence-Based Medicine, Translational Medicine, Cardiovascular Research
Introduction
Cardiovascular diseases remain among the leading causes of global morbidity and mortality, thereby necessitating continuous scientific advancements in prevention, diagnosis, and therapeutic intervention. Clinical cardiology research plays a significant role in improving patient outcomes through observational studies, pharmacological assessments, and evidence-driven treatment approaches. David Suran has contributed to this research landscape through publications addressing cardiovascular complications, myocardial infarction management, renal impairment in cardiovascular conditions, and clinical predictors associated with adverse cardiovascular outcomes.[3]
His academic and clinical work demonstrates integration between hospital-based medical practice and scholarly research activities. Publications indexed through Scopus and ORCID indicate active participation in collaborative research initiatives involving cardiovascular medicine, nephrology, metabolic disorders, and public health-related cardiovascular investigations.[4]
Research Profile
David Suran is affiliated with Maribor University Medical Centre in Slovenia and serves in academic and clinical capacities associated with cardiology and cardiovascular medicine. ORCID records indicate involvement in internal medicine specialization, cardiovascular medicine specialization, and biomedical technology research training.[5]
The researcher’s Scopus profile records 310 documents, 332 citations, and an h-index of 11, reflecting sustained scholarly activity in cardiovascular medicine and related interdisciplinary areas. His research portfolio demonstrates thematic continuity in myocardial infarction studies, atrial fibrillation management, renal dysfunction following cardiovascular intervention, and prognostic cardiovascular biomarkers.[1]
- Clinical specialization in cardiology and cardiovascular medicine
- Research emphasis on myocardial infarction and cardiovascular complications
- Peer-reviewed contributions to nephrology and cardiovascular outcomes research
- Participation in collaborative translational medicine studies
- Integration of evidence-based medicine within clinical cardiology practice
Research Contributions
A significant portion of Suran’s research has focused on cardiovascular risk assessment and patient outcomes in myocardial infarction populations. Publications investigating lipoprotein(a), acute kidney injury, obesity-related cardiovascular complications, and atrial fibrillation recurrence contribute to contemporary cardiovascular clinical understanding.[6]
Several studies have explored relationships between cardiovascular biomarkers and patient prognosis in acute myocardial infarction. Research addressing anemia, renal deterioration after percutaneous coronary intervention, and inflammatory or metabolic risk factors illustrates the clinical relevance of his investigations in routine medical practice.[3]
Additional investigations involving machine learning applications in medicine and explainable artificial intelligence demonstrate interdisciplinary engagement beyond traditional cardiovascular pharmacology. These contributions indicate evolving participation in digital health analytics and data-driven clinical methodologies.[3]
Publications
David Suran’s publications focus on cardiovascular pharmacology, myocardial infarction outcomes, atrial fibrillation, and renal complications associated with cardiovascular disease. His research includes clinical studies on lipoprotein(a), acute kidney injury, cardiovascular risk prediction, and interventional cardiology methodologies. Several works also examine evidence-based therapeutic approaches and translational medical applications in cardiovascular medicine.[4]
Research Impact
The scholarly contributions of David Suran demonstrate measurable academic engagement through peer-reviewed publications, interdisciplinary collaboration, and citation visibility in cardiovascular medicine. His work contributes to ongoing clinical discussions concerning myocardial infarction prognosis, cardiovascular complications, and evidence-based therapeutic approaches.[3]
Research outputs indexed in Scopus and ORCID further indicate continuity of scientific productivity and participation in internationally accessible medical literature databases. Studies involving cardiovascular risk biomarkers, renal complications, and outcome-based analyses hold practical significance for clinical cardiology and cardiovascular pharmacology research communities.[4]
Award Suitability
The Best Researcher Award recognizes individuals demonstrating sustained academic productivity, research quality, interdisciplinary collaboration, and meaningful scholarly contributions within their respective domains. David Suran’s publication profile, clinical research involvement, and documented scientific outputs indicate alignment with the evaluative expectations associated with international academic recognition programs.[4]
His research contributions to cardiovascular pharmacology and clinical cardiology demonstrate consistency in peer-reviewed dissemination, evidence-oriented investigation, and participation in clinically relevant scientific studies. The integration of cardiovascular outcomes research with practical clinical observations further strengthens the academic significance of his work within pharmaceutical and medical research communities.[4]
Conclusion
David Suran has established a research profile centered on cardiovascular medicine, myocardial infarction outcomes, and translational clinical investigations. His scholarly work reflects contributions to evidence-based cardiovascular research, interdisciplinary medical collaboration, and clinically applicable scientific inquiry. Through publications indexed in internationally recognized databases, Suran continues to contribute to the advancement of cardiovascular pharmacology and related medical sciences. The cumulative body of work supports his recognition within professional academic award frameworks focused on research excellence and clinical impact.[4]
External Links
References
- Elsevier. (n.d.). Scopus author details: David Suran, Author ID 26650243300. Scopus.https://www.scopus.com/authid/detail.uri?authorId=26650243300
- ORCID. (n.d.). David Suran ORCID profile and publication summary.https://orcid.org/0000-0002-4073-9286
- Suran, D. et al. (2024). Lipoprotein(a) as a Risk Factor for Recurrent Acute Myocardial Infarction and Mortality. Diagnostics.https://doi.org/10.3390/diagnostics14232757
- Suran, D. et al. (2023). Obesity and Acute Kidney Injury in Patients with ST-Elevation Myocardial Infarction. Journal of Clinical Medicine.https://doi.org/10.3390/jcm12237311
- ORCID. (n.d.). Professional activities and academic qualifications of David Suran.https://orcid.org/0000-0002-4073-9286
- Suran, D. et al. (2022). Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study. Frontiers in Public Health.https://doi.org/10.3389/fpubh.2022.923797
- Suran, D. et al. (2019). Impact of KDIGO-Defined Acute Kidney Injury on Mortality after Percutaneous Coronary Intervention. Cardiorenal Medicine.https://doi.org/10.1159/000492287